Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13427MR)

This product GTTS-WQ13427MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13427MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5789MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ7162MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ12677MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ15204MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ10993MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ15795MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ5355MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ11629MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MGD-013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW